



**California State Board of Pharmacy
Department of Consumer Affairs
Public Board Meeting Minutes**

Date: June 19-20, 2025

Location: OBSERVATION AND PUBLIC COMMENT IN PERSON:
California Department of Consumer Affairs
1625 N. Market Blvd., Hearing Room, First Floor
Sacramento, CA 95834

PUBLIC PARTICIPATION AND COMMENT FROM A
REMOTE LOCATION: Webex

Board Members

Present: Seung Oh, PharmD, Licensee Member, President
Trevor Chandler, Public Member, Treasurer
Renee Barker, PharmD, Licensee Member
Jeff Hughes, Public Member
Kartikeya "KK" Jha, RPh, Licensee Member (via Webex)
Claudia Mercado, Public Member
Jason "Jay" Newell, MSW, Public Member
Ricardo Sanchez, Public Member
Satinder Sandhu, PharmD, Licensee Member
Maria Serpa, PharmD, Licensee Member
Nicole Thibeau, PharmD, Licensee Member (via Webex)

Board Members

Not Present: Jessica Crowley, PharmD, Licensee Member, Vice President

Staff Present:

Anne Sodergren, Executive Officer
Julie Ansel, Deputy Executive Officer
Lori Martinez, Chief of Legislation, Policy and Public Affairs
(6/19/25 only)
Sara Jurens, Public Information Officer (6/20/25 only)
Corinne Gartner, DCA Staff Counsel
Shelley Ganaway, DCA Staff Counsel
Jennifer Robbins, DCA Regulations Counsel
Debbie Damoth, Senior Administration Manager
Julie McFall, Executive Specialist Manager

June 19, 2025

I. Call to Order, Establishment of Quorum, and General Announcements (Including Possible Notifications, Actions, and Disclosures Pursuant to Government Code section 11123.2(j))

President Oh called the Board meeting to order at 1:00 p.m. President Oh welcomed Claudia Mercado as the newest appointee to the Board and congratulated members Thibeau, Jha, and Newell on their reappointments.

President Oh reminded all individuals present that the Board is a consumer protection agency charged with administering and enforcing Pharmacy Law. Where protection of the public is inconsistent with other interests sought to be promoted, the protection of the public shall be paramount.

Roll call was taken. The following Board members were physically present in Sacramento: Trevor Chandler, Public Member; Jeff Hughes, Public Member; Jay Newell, MSW, Public Member; Ricardo Sanchez, Public Member; Satinder Sandhu, PharmD, Licensee Member; Maria Serpa, PharmD, Licensee Member; and Seung Oh, PharmD, Licensee Member. KK Jha, RPh, Licensee Member and Nicole Thibeau, PharmD, Licensee Member participated via Webex. Mr. Jha and Dr. Thibeau each disclosed that no persons over 18 years old were present in the room with them as they participated in the meeting remotely via Webex. A quorum was established.

Member Mercado arrived at 1:08 p.m.

II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings

Members of the public participating from Sacramento were provided the opportunity to comment. The Board heard two comments from members of the public who spoke about concerns about COVID-19 vaccines.

Members of the public participating via Webex were provided the opportunity to comment. The Board heard a comment from a member of the public who felt it would be nice to show the name of the person speaking on screen. The Board also heard a comment from a representative from CPhA regarding the Rite Aid closures.

Members were provided the opportunity to comment. Members requested an agenda item to discuss the Rite Aid closures. Ms. Sodergren noted this item would be included in the Executive Officer Report.

III. Recognition and Celebration of Pharmacists Licensed in California for 40 Years

President Oh advised the Board's recognition of pharmacists licensed in California for over 40 years was posted on the Board's website and pharmacists were provided with a certificate when they reach this significant milestone. President Oh invited pharmacists licensed for 40 years or more to identify themselves and be recognized by the Board. President Oh thanked all pharmacists who worked in pharmacy serving the consumers of California.

IV. Approval of Board Meeting Minutes

a. April 9-10, 2025 Board Meeting

President Oh referenced the draft minutes from the April 9-10, 2025 Board meeting. Members were provided an opportunity to comment; however, no comments were made.

Motion: Approve the April 9-10, 2025 Board meeting minutes as presented in the meeting materials.

M/S: Sanchez/Newell

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment.

A member of the public had a comment on items not on the agenda and President Oh approved the request to comment. The individual commented in opposition to the cultural competency CE requirement.

Member Barker arrived at approximately 1:28 p.m.

Members were provided the opportunity to comment; however, no members provided comments.

President Oh returned to the approval of the minutes and restated the motion.

Support: 10 Oppose: 0 Abstain: 1 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Abstain
Serpa	Support
Thibeau	Support

b. May 21, 2025 Disciplinary Petition Committee Meeting

President Oh referenced the draft minutes from the May 21, 2025 Disciplinary Petition Committee meeting. Members were provided an opportunity to comment; however, no comments were made.

Motion: Approve the May 21, 2025 Disciplinary Petition Committee meeting minutes as presented in the meeting materials.

M/S: Chandler/Sanchez

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

V. Report by the California Department of Consumer Affairs

The Board heard a report from Shelly Jones on behalf of the Department of Consumer Affairs.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

VI. Discussion and Consideration of the Board's Strategic Plan

President Oh advised that on an annual basis, the Board reviews its strategic plan to ensure the established strategic objectives for each committee remain appropriate or if changes should be considered. This annual review also serves as an opportunity for the Board to evaluate progress in the respective areas. He noted that, as reflected in the meeting materials, no committees were recommending changes to their respective objectives.

As Chairperson of the Licensing Committee, Dr. Oh reported the status of the objectives established and reported making steady progress on the strategic objectives with continued activities in support of the strategic objectives.

Members were provided an opportunity to comment on Dr. Oh's report; however, no comments were made.

Chairperson Serpa of the Enforcement and Compounding Committee provided an overview of the Committee's strategic objectives. Dr. Serpa was proud of the Committee's accomplishments and looked forward to continued efforts.

Dr. Serpa acknowledged the progress staff made to meeting the strategic objective in 2.3, noting great strides were made to reach the four-year inspection goal.

Dr. Serpa also acknowledged the progress made in meeting strategic objective 2.4. Proposed amendments to Business and Professions Code (BPC) sections 4081 and 4105 were included in the Board's sunset measure, AB 1503. In addition, the Board implemented a new digital process to streamline the investigative process and reduce investigation time frames.

Dr. Serpa next highlighted that the Committee had been working on strategic goal 2.5 for several years, and provisions to transition pharmacist practice to a more robust standard of care practice model were included in AB 1503.

Related to strategic objective 2.8, Dr. Serpa noted that the Board implemented a

new learning management system for licensees to complete Board-provided continuing education (CE), including the newly required PIC training course. She further noted that strategic objective 2.10, regarding the Board's compounding regulations, resulted in five formal comment periods, a regulatory hearing, and extensive review and discussion over the course of multiple public meetings. The Board approved final regulatory text in March 2025 and thereafter submitted the final rulemaking file to the Office of Administrative Law.

Finally, Dr. Serpa highlighted that the Committee added strategic objective 2.11, regarding evaluating barriers to consultation, in November of 2024. The Committee planned to discuss this issue at a future meeting.

Vice Chairperson Thibeau of the Legislation and Regulation Committee then provided the Committee's report on its six strategic objectives. Dr. Thibeau referenced the meeting materials providing updates to the respective objectives and noted that the Committee believed the objectives remained appropriate.

Chairperson Thibeau of the Communication and Public Education Committee provided the Committee's report on its eight strategic objectives. The Committee identified areas where additional actions were required. As an example, the Committee would be evaluating additional opportunities to engage with consumers more directly as well as evaluating opportunities to recognize pharmacists. The Committee believed the objectives remained appropriate.

Next, President Oh reported the status of the objectives established for the Organizational Development Committee, which is composed of the Board President and Vice-President who meet with the Executive Officer to discuss items under the purview of the Committee. Dr. Oh noted several activities had been undertaken in support of the Committee's strategic objectives. President Oh highlighted some of the training completed by Board staff under objective 5.3 and strategic objective 5.4 related to business modernization activities, as well as work to update information on the Board's website related to strategic objective 5.6.

Board members were provided an opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via WebEx were provided an opportunity to comment; however, no comments were made.

VII. Discussion and Possible Action Regarding Executive Officer Exempt Level Change and Salary Increase

President Oh noted that he had been conferring with the Department of Consumer Affairs on the process to request a change in the exempt level and salary of the executive officer position. President Oh referenced meeting materials which included a memo detailing the justification for a change.

President Oh introduced Olivia Trejo, Department of Consumer Affairs Chief of Office of Human Resources (DCA OHR) who was present to answer any questions.

Motion: Delegate to the Board President to submit requests to the Department of Consumer Affairs and CalHR to (1) change the exempt level of the Board's executive officer (EO) position to "none"; (2) specify a salary range for the EO position with a monthly minimum equal to the EO's current monthly salary and a monthly maximum equal to the current monthly salary plus up to 10%; and (3) increase the monthly salary of the current executive officer to an amount equal to the current monthly salary plus up to 10%.

M/S: Sanchez/Serpa

Members were provided the opportunity to comment.

Members articulated strong support for the motion and provided additional justifications for the change including lack of parity with other positions, and the knowledge, accessibility, and national stature of the executive officer.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A pharmacist expressed strong support for the motion, noting the executive officer of the Board of Pharmacy needed to have broader and deeper expertise than executive officers of other DCA boards.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

VIII. Closed Session

Open session concluded at approximately 2:03 p.m. The Board entered closed session at approximately 2:33 p.m. Closed session ended at 5:09 p.m.

IX. Reconvene in Open Session to Adjourn the Meeting

The Board reconvened into open session and adjourned the meeting at 5:09 p.m.

June 20, 2025

President Oh called the Board meeting to order at approximately 9:00 a.m. Dr. Oh reminded individuals participating in the meeting via Webex that consistent with the Board's policy and with implementation of the Board's new learning management system, pharmacists and pharmacy technicians attending the meeting via Webex may be awarded up to six hours of CE. Dr. Oh referred individuals to the information on the agenda for additional information. Individuals seeking CE were required to register through the Board's learning management system.

Dr. Oh reminded all individuals present that the Board is a consumer protection agency charged with administering and enforcing Pharmacy Law. Where protection of the public is inconsistent with other interests sought to be promoted, the protection of the public shall be paramount.

Roll call was taken. The following Board members were physically present in Sacramento: Trevor Chandler, Public Member; Renee Barker, PharmD, Licensee Member; Jeff Hughes, Public Member; Claudia Mercado, Public Member; Jay Newell, MSW, Public Member; Ricardo Sanchez, Public Member; Satinder Sandhu, PharmD, Licensee Member; Maria Serpa, PharmD, Licensee Member; and Seung Oh, PharmD, Licensee Member. KK Jha, RPh, Licensee Member and Nicole Thibeau, PharmD, Licensee Member participated via Webex. Mr. Jha and Dr. Thibeau each disclosed that no persons over 18 years old were present in the room with them as they participated in the meeting remotely via Webex. A quorum was established.

Dr. Oh reminded members participating via Webex to keep their cameras on throughout the open portion of the meeting. Dr. Oh requested members announce the reason for their nonappearance if they needed to turn their camera off temporarily due to internet connectivity issues.

X. Discussion and Possible Action Related to Proposed Regulations, Title 16, California Code of Regulations, Repeal of Sections 1708.3, 1708.4, 1708.5, 1735 et seq., and 1751 et seq. and Addition of Sections 1735 et seq., 1736 et seq., 1737 et seq., and 1738 et seq. Related to Compounded Drug Preparations, Hazardous Drugs, and Radiopharmaceuticals in Response to Comments from the Office of Administrative Law, if Any Received

President Oh advised this item was placed on the agenda in the event the Office of Administrative Law required action by the Board to address any issues that arose through their review of the Board's regulation. As no comments were received from the Office of Administrative Law, discussion of this item was not required.

XI. Discussion and Possible Action Related to Proposed Amendment to California Code of Regulations, Title 16, Section 1713 Related to Automated Patient Delivery Systems (APDS) Consultation

President Oh provided background on the item and noted no comments were received in response to the Board's 45-day comment period.

Members were provided the opportunity to comment. Dr. Oh explained the different types of APDS systems in response to a question from a member. Members discussed how the proposed changes will conform the requirement in section 1713(d)(3) to a requirement in Business and Professions Code section 4427.6 (specifically in subsection (f)), which was enacted years after the regulation section was created. Members discussed two-way video and audio consultation.

Motion: Adopt the proposed regulation at Section 1713 as noticed on February 21, 2025, and authorize the Executive Officer to take all steps necessary to complete the rulemaking. Further, delegate to the Executive Officer the authority to make technical or non-substantive changes as may be required by the Control agencies to complete the rulemaking file.

M/S: Barker/Sandhu

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A member of the public stated that the statute defines an APDS as a "dispensing" system and not a "delivery" system.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

XII. Discussion and Possible Action Related to Proposed Amendment to California Code of Regulations, Title 16, Section 1711 Related to Quality Assurance Programs, Including Review of Comments Received During the Second 15-Day Comment Period

President Oh provided background information related to the regulation, noting the one-year deadline was approaching, and staff were recommending that the Board withdraw the current rulemaking to allow the Board to further discuss the proposed regulations.

Dr. Oh advised that the proposed regulations were approved by the Board prior to the enactment of the Board's patient safety measure, AB 1286 (Haney, Chapter 470, Statutes of 2023). Dr. Oh believed it was appropriate to withdraw the rulemaking and refer the matter back to the Enforcement and Compounding Committee to allow members to review the proposed changes and confirm the language was still appropriate.

Members were provided the opportunity to comment. Members discussed possible next steps, including delegating to members Serpa and Jha to work with staff to develop language for presentation to the Enforcement and Compounding Committee.

Motion: Withdraw the rulemaking and delegate to members Serpa and Jha to work on the language with Board staff before bringing it to the Enforcement and Compounding Committee.

M/S: Serpa/Barker

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative of Kaiser Permanente spoke in favor of keeping changes to the regulation high level, consider what was missing, and be consistent with Just Culture principles.

Member Serpa requested that staff review SB 1875 (Speier, Chapter 816, Statutes of 2000) which was the original legislation behind the regulation.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

XIII. Communication and Public Education Committee Report

Chairperson Thibeau provided the report on the Communication and Public Education Committee's meeting on June 12, 2025. Dr. Thibeau thanked fellow Committee members Jay Newell, Renee Barker, Claudia Mercado, and Ricardo Sanchez.

a. Education Materials on Buprenorphine

Dr. Thibeau recalled the Board heard a presentation at the February 2025 Board meeting about the challenges patients and pharmacists face related to receiving addiction medication such as buprenorphine.

Dr. Thibeau explained to educate pharmacists on how to handle these situations, Board staff created educational material on buprenorphine that could additionally be sent as a subscriber alert, included in the newsletter, and posted on the website. Committee members reviewed the educational material and offered feedback regarding the messaging and suggested developing a continuing education course focused on dispensing buprenorphine.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

b. Update on Communication and Public Education Activities by Staff

1. The Script

The Board released an issue of *The Script* newsletter in May 2025, which is posted on the Board's website.

2. Staff Outreach

Staff provided outreach through several presentations and trainings as indicated in the meeting materials.

3. News Media Inquiries

The meeting materials included a list of news media inquiries.

Members were provided the opportunity to comment. Members discussed news media inquiries.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Members were provided an opportunity to comment. Member Mercado recalled wanting to invite DCA to audit how the Board was represented in social media to ensure public accessibility.

XIV. Enforcement and Compounding Committee Report

Chairperson Serpa provided the report on the Enforcement and Compounding Committee's meeting on June 11, 2025. Dr. Serpa thanked fellow Committee members Vice Chairperson Renee Barker, Jeff Hughes, Seung Oh, Ricardo Sanchez, and Nicole Thibeau.

a. Summary of Presentation on Board's Inspection Program

Dr. Serpa reported that at the meeting, the Committee received the annual presentation providing summary information detailing accomplishments towards strategic objective 2.3 of the Board's strategic plan, which calls for completion of routine inspections of all licensed pharmacies at least every four years. She commented on the significant efforts of Board staff to achieve this objective.

Dr. Serpa advised Committee members requested subsequent inspection presentation data be broken down by license category.

Dr. Serpa noted that members discussed adding a reference section on the inspection report, and drafting a fact sheet or writing a *Script* article to clarify specific terminology for licensees to define terms such as orders of correction, violations, and written notice. Members agreed providing education may help licensees to understand the inspection process, terminology, and outcomes. The Committee suggested this issue be referred to the Communication and Public Education Committee.

Members were provided the opportunity to comment. Dr. Oh thanked the inspectors for all the work they have done to accomplish the strategic goal. Members reiterated the appreciation and discussed the importance of having a fact sheet on violations and corrections and providing written next steps. Inspectors were available for questions and leave business cards with their contact information at the location after an inspection.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A pharmacist spoke in support of the discussion and noted that when inspections occur, the PIC is not always present, so the inspector might be dealing with a less experienced staff member.

Members were provided the opportunity to comment; however, no comments were made.

b. Summary of Presentation on Board's Citation and Fine Program

Dr. Serpa reported the Committee received a presentation annually regarding the citation and fine program, which included information on common violations. The information was shared during the annual presentation and was included in the Board's newsletter to provide education to licensees about the most common violations for which citations are issued.

Dr. Serpa advised the Committee appreciated that staff reported the citation data by license type. Members noted the decrease in the overall citations issued in fiscal year 24/25, noting staff's focus on internal norming of case investigations and inspector education of licensees.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

c. Summary of Presentation on Quality Assurance Reports Received Pursuant to California Code of Regulations, Title 16, Section 1711(f) Related to the Use of

Automated Drug Delivery Systems

Dr. Serpa advised that BPC section 4427.8 required the Board, on or before January 1, 2025, to report to the Legislature on the regulation of automated drug delivery system (ADDs) units as part of the sunset evaluation process. This report was submitted to the Legislature in January of 2025. In addition, Title 16 CCR Section 1711(f) established an ongoing reporting requirement for any quality assurance record related to the use of an ADDs.

Dr. Serpa noted the Committee received a presentation related to the findings of the Quality Assurance (QA) reports annually. Members noted there may be issues with underreporting QA records for ADDs and confusion among the regulated public on reporting requirements, making it challenging to evaluate the error reports provided.

Dr. Serpa advised the Board will continue its outreach and education efforts. Committee members suggested staff review the ADDs FAQs and offer recommendations for possible updates. Members also suggested that staff develop a standardized template for reporting of ADDs QA reports under Title 16 CCR Section 1711(f), to aid with compliance and consistency in data elements.

Members were provided the opportunity to comment. Members discussed the idea of developing a reporting template that could help to identify the cause or what contributed to the error. Members also discussed looking at if there was still a value in the reporting of ADDs errors. Members discussed the idea of engaging with vendors to assist with analytics. Members noted organizations can bypass safety parameters and vendors may not have all the elements needed for each state which require additional cost. Dr. Barker noted the self-assessment form for ADDs was a valuable resource. Members discussed the need for education on the reporting requirements.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative of Kaiser Permanente expressed support for evaluating the continued need for reporting of ADDs errors to the Board and suggested the underlying reason for the regulation no longer exists. A representative from Scripps Health suggested QA reports were peer-reviewed and protected information. The representative expressed concern that requesting this protected information would reduce the effectiveness of the peer review process. The representative further suggested the way errors were defined in FAQs 6 and 7 of the ADDs FAQs caused confusion.

Dr. Serpa indicated that the Committee would continue to discuss the definition of medication errors and review the FAQs. The Committee discussed protected information and noted there was nothing in the QA report that required protected information.

- d. Discussion and Consideration of Updates to Frequently Asked Questions Related to the Board's Ask An Inspector Program

Dr. Serpa noted that the meeting materials included a copy of the updated FAQs. Dr. Serpa reported Committee members spoke in support of the updates to the FAQs and based on Committee discussion staff made additional updates. The Committee would continue the discussion regarding question 18. Ultimately, it may be advisable to develop regulations addressing the wearing of identification, as interpretive questions with the word "name" in BPC section 680 were noted.

Committee Motion: Recommend approval of the updated FAQs related to the Board's Ask An Inspector Program consistent with the Committee's discussion.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative from Scripps Health requested that BPC 680 be added to the pharmacy law book. Board staff was directed to research why this section was not in the lawbook.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

- e. Discussion and Consideration of Updates to Frequently Asked Questions Related to Assembly Bill 1286 (Haney, Chapter 470, Statutes of 2023)

Dr. Serpa recalled given the comprehensive nature of AB 1286, the development of FAQs was determined appropriate. Dr. Serpa reported the Board approved the Institute for Safe Medication Practices (ISMP) as the entity to receive medication error reports from community pharmacies under BPC section 4113.1. Board staff updated the FAQs to include this information as well as additional information about the California Medication Error Reporting (CAMER) program, including registration and fee information for licensees.

Committee Motion: Recommend approval of the updated FAQs related to Assembly Bill 1286 as presented.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative from Scripps Health suggested adding an FAQ for clarity of which pharmacies need to report to ISMP. The Board discussed hospital licensure and when a hospital would need a PHY license and referred to BPC section 4113.1(c) on the definition of a community pharmacy. Dr. Serpa indicated the Committee would explore making that an FAQ during the next updates.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

The Board took a break from 10:35 a.m. to 10:50 a.m.

Roll call was taken. The following Board members were physically present in Sacramento: Trevor Chandler, Public Member; Renee Barker, PharmD, Licensee Member; Jeff Hughes, Public Member; Claudia Mercado, Public Member; Jay Newell, MSW, Public Member; Ricardo Sanchez, Public Member; Satinder Sandhu, PharmD, Licensee Member; Maria Serpa, PharmD, Licensee Member; and Seung Oh, PharmD, Licensee Member. KK Jha, RPh, Licensee Member and Nicole Thibeau, PharmD, Licensee Member participated via Webex. A quorum was established.

- f. Discussion, Consideration, and Possible Action on Proposal to Add New Section 1707.51 Related to Accessible Prescription Drug Labels to Article 2 of Division 17 of Title 16 of the California Code of Regulations

Dr. Serpa provided background on this item and recalled that during the April 2025 meeting, the Board directed staff to develop proposed regulation text for consideration. During the June Committee meeting, members discussed draft regulatory language developed by staff. Members were in support of the draft language and suggested that drafting FAQs on the topic in the future may also be appropriate. Public comment during the Committee meeting suggested that section (b) of the proposed regulation, which requires pharmacy personnel to sign a copy of the policies and procedures, should be removed. After discussion, members did not reach a consensus on whether to keep or remove section (b). Accordingly, section (b) was left in to allow the full Board to consider the issue.

Dr. Serpa noted that the meeting materials included the draft regulatory language.

Motion: Initiate a rulemaking to add California Code of Regulations, Title 16, section 1707.51 consistent with the Board's discussion. Authorize the executive officer to further refine the language consistent with the Board's discussion. Direct Board staff to submit the text to the Director of the Department of Consumer Affairs and the Business, Consumer Services, and Housing Agency for review, and if no adverse comments are received, authorize the executive officer to take all steps necessary to initiate the rulemaking process, and set the matter for hearing if requested. If, during the 45-day comment period, the Board does not receive any comments providing objections or adverse recommendations specifically directed at the proposed action or to the procedures followed by the Board in proposing or adopting the action, and no hearing is requested, authorize the executive officer to take all steps necessary to complete the rulemaking process and adopt the proposed regulation at section 1707.51. Finally, delegate to the executive officer the authority to make technical or non-substantive changes as may be required by the Control agencies to complete the rulemaking file.

M/S: Serpa/Chandler

Members were provided the opportunity to comment. After discussion, members agreed that omitting (b) was appropriate. Members also agreed it was appropriate to add language into (a)(4) permitting electronic recordkeeping in lieu of physical signing.

Members of the public participating in Sacramento were provided the opportunity to comment. A representative of CVS Health commented (b) is an administrative burden and the Board should allow flexibility to the business.

Members of the public participating via Webex were provided the opportunity to comment. A member from CVS Health agreed with the removal of (b). A member from Kaiser Permanente agreed that consolidating (b) into (a)(4), and allowing for electronic maintenance of the records, was the right approach. A member of the public commented that there may be a conflict between CLAS and the existing patient centered labeling requirements, and pharmacies may need help understanding how to reconcile the two requirements.

Board Members were provided opportunity to comment. Members requested the Board consider language such that pharmacies meet the *intent* of the requirement and help patients (as opposed to pharmacies simply meeting the requirement without actually helping patients). Another member requested the Board consider expanding (a)(4) to detail out the type of training topics and policies covering accessibility.

Members discussed adding language to (a)(4) stating that the policies and procedures also describe the training provided to pharmacy personnel on policies and procedures related to prescription label accessibility (as a way of helping ensure that not only do those policies and procedures exist, but that personnel are actually trained on those policies and procedures). Members also discussed adding language to (a)(4) that the training in (a)(4) be documented.

In response to a member's question, Ms. Sodergren explained the statute references specific sources for people to consider, including best practices established by the United States Access Board and The National Standards for Culturally and Linguistically Appropriate Services in Health.

Dr. Serpa reminded everyone that the motion was to begin the rulemaking process, which requires multiple steps including formal written comment periods.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

g. Discussion and Consideration of Enforcement Statistics

This item was not discussed.

XV. Legislation and Regulation Committee Report

Vice Chairperson Thibeau provided a report on the Legislation and Regulation Committee's meeting held on June 11, 2025. Dr. Thibeau thanked fellow Committee members, Chair Jessica Crowley, and members Trevor Chandler, Maria Serpa, and KK Jha. Dr. Thibeau advised May 23, 2025 was the last day for fiscal committees to hear and report to the Floor for their respective house. The next legislative deadlines included July 18, 2025, as the last day for policy committees to meet prior to Summer Recess.

Dr. Thibeau noted a few measures previously considered by the Board were not included as they did not make it out of committee this year and would not be discussed, including Senate Bill 548.

a. Discussion and Consideration of Pending Legislation Impacting the Practice of Pharmacy, the Board's Jurisdiction, or Board Operations

1. Assembly Bill 50 (Bonta, 2025) Pharmacists: Furnishing Contraceptives

Dr. Thibeau advised this measure would update provisions related to pharmacist-furnished hormonal contraceptives to explicitly allow pharmacists to furnish over-the-counter contraception without following the standardized procedures required for prescription-only hormonal contraception. Further, the measure would allow for the furnishing of up to a 12-month supply at one time of OTC contraceptives. The Senate Appropriations Committee would consider this measure on June 23, 2025. The Board established a support position on this measure. The Committee was not recommending any changes to the Board's current position.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

2. Assembly Bill 309 (Zbur, 2025) Hypodermic Needles and Syringes

Dr. Thibeau advised AB 309 would make permanent provisions to allow pharmacists to furnish hypodermic needles and syringes for personal use. The Senate Health Committee considered this measure on June 18, 2025. Dr. Thibeau reported AB 309 passed out of the Senate Health Committee and was referred to the Senate Business, Professions, and Economic Development Committee. The Legislation and Regulation Committee was recommending the Board establish a support position on the measure. The Committee received no public comment on the measure during its June 11, 2025 meeting.

Committee Recommendation: Establish a support position

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

3. Assembly Bill 447 (González, 2025) Emergency Room Patient Prescriptions: Dispensing Unused Portions Upon Discharge

Dr. Thibeau advised AB 447 would allow a prescriber to dispense an unused portion of a dangerous drug acquired by the hospital pharmacy to an emergency room patient under specified conditions, including dispensing the unused portion of the dangerous drug if required to continue treatment of the patient. As amended, it would exempt from licensure an AUDS that was used to dispense to emergency room patients.

Dr. Thibeau advised during the last meeting the Board did not discuss AB 447 since amendments to the measure were not yet in print. The amendments in the measure appear to provide clarification in some areas.

The Committee believed the Board should continue to watch this measure. This measure was moving quickly, and the Senate Business, Professions, and Economic Development Committee will consider this measure on June 23, 2025.

Members were provided the opportunity to comment. Dr. Serpa expressed concern about this measure and agreed the Board should watch it closely. Dr. Serpa believed labeling and documentation were necessary since the product belongs to the hospital pharmacy's inventory. This bill would bypass the documentation. She also expressed concerns about unlabeled medications going out as well as possible missing medications from the pharmacy inventory. Additionally, the emergency room AUDS was required to be licensed since medications were sent outside the hospital. Eliminating the licensure would mean the Board would receive error reports annually rather than within the 30-day period.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

4. Assembly Bill 529 (Ahrens, 2025) Pharmacy: Declared State of Emergency

Dr. Thibeau advised Assembly Bill 529 would extend the Board's authority to continue to waive provisions of pharmacy law for up to 120 days following the termination of a declared emergency. The Senate Appropriations Committee was scheduled to consider this measure on June 23, 2025. The Board established a support position on this measure. The Committee believed the Board's current position remained appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

5. Assembly Bill 669 (Haney, 2025) Substance Use Disorder Coverage

Dr. Thibeau advised AB 669 would ensure 28 days of inpatient, intensive outpatient, or partial hospitalization for substance use disorder treatment for patients. The measure would also prohibit insurers from requiring prior authorization for FDA-approved medications used to treat addiction that were deemed medically necessary by a doctor. The provisions would become effective January 1, 2027. This measure has been referred to the Committee on Rules for assignment.

The Board established a support position on this measure. The Committee believes the Board's current position remains appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

6. Assembly Bill 957 (Ortega, 2025) Cigarette and Tobacco Products: Retail Sale: Pharmacies

Dr. Thibeau advised AB 957 would prohibit a pharmacy from selling cigarettes or tobacco products. This measure was moving quickly and would be considered by the Senate Business, Professions, and Economic Development Committee on June 30, 2025. Dr. Thibeau reported the Board established a support position on this measure. The Committee believed the Board's current position remained appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Members were provided another opportunity to comment. Member Mercado inquired about pharmacies that are currently selling these items. Ms. Sodergren confirmed with counsel the bill would prohibit any establishment that has a pharmacy within it from being issued or renewed a license to sell tobacco products.

7. Assembly Bill 968 (Boerner, 2025) Pharmacists: Self-Administered FDA-approved Nonhormonal Contraceptives

Dr. Thibeau advised AB 968 would allow a pharmacist to furnish a 12-month supply of an FDA-approved, self-administered nonhormonal contraceptive at the patient's request. Dr. Thibeau noted this was the first time the Committee considered this measure. This measure was scheduled to be considered during the Senate Business, Professions, and Economic Development Committee hearing on June 23, 2025.

As amended, the measure would update that authority to authorize pharmacists to furnish "prescription-only" (hormonal and non-hormonal) contraceptives in accordance with a standardized protocol. The Committee was recommending the Board establish a support position on the measure. Dr. Thibeau noted that the Committee reviewed the prior version of this measure; however, with the recent amendments, it was appropriate for the Board to consider the measure in its current form.

Dr. Thibeau believed the Committee's recommendation to establish a support position was still appropriate.

Committee Recommendation: Establish a support position

Members were provided the opportunity to comment. Members discussed the differences between hormonal and non-hormonal contraceptives.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

8. Assembly Bill 1460 (Rogers, 2025) Prescription Drug Pricing

Dr. Thibeau advised AB 1460 would prohibit a prescription drug manufacturer from engaging in discriminatory practices that would impose additional conditions or otherwise interfere with a covered entity's purchase or delivery of a drug subject to federal pricing requirements under specified conditions. The Senate Health Committee would consider this measure on June 25, 2025.

Dr. Thibeau noted the Committee raised concerns about the changes being sought to restrict 340B programs and the negative impacts to such programs. She noted this measure could address some of these issues. Members noted that 340B federal programs plays a vital role in providing services to underserved communities at a reduced cost.

The Board established a support position on this measure. The Committee believes the Board's current position remained appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Members were provided another opportunity to comment. Members discussed the effects of PBMs and discriminatory practices.

9. Assembly Bill 1503 (Berman, 2025) Pharmacy

Dr. Thibeau advised AB 1503 was the Board's sunset measure. As amended, the measure would extend the Board's operations until January 1, 2030. The measure encompassed several policy issues highlighted by the Board in its Sunset Report. In addition to the Board-sponsored provisions, the measure included a provision to require the Board to establish and appoint a Pharmacy Technician Advisory Committee. In addition, the proposed ratio provisions in the measure exceed those recommended by the Board. Specifically, the measure would authorize the pharmacist-in-charge (PIC) to establish a ratio of up to four pharmacy technicians for each pharmacist. This measure was schedule to be considered during the Senate Business, Professions, and Economic Development Committee hearing on June 30, 2025.

The Board established a support position on this measure. Committee members believe the Board's current position remains appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative of CPhA expressed appreciation for the Board's work and spoke in support of the measure.

10. Senate Bill 40 (Wiener, 2025) Health Care Coverage: Insulin

Dr. Thibeau advised SB 40 would prohibit a health care service plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin and would establish a cap on the cost for a 30-day supply of insulin. The Assembly Health Committee was scheduled to consider this measure on June 24, 2025.

The Committee recommended the Board establish a support position on the measure. The Committee received no public comment on the measure at its June 11, 2025 meeting.

Committee Recommendation: Establish a support position

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Members were provided another opportunity to comment. Members clarified "source" was the sponsor of the bill.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

11. Senate Bill 41 (Wiener, 2025) Pharmacy Benefits

Dr. Thibeau advised as amended, SB 41 would establish the regulation of Pharmacy Benefits Managers (PBMs) within the Department of Insurance. The measure was double referred to the Assembly Health and Judiciary Committees. Dr. Thibeau advised the Board has received public comments and complaints from consumers and health care providers stemming from actions by PBMs.

This measure was similar to Senate Bill 966 from last year, that was supported by the Board but was vetoed by the governor.

The Board established a support position on this measure. The Committee believes the Board's current position remains appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative of CPhA, the sponsor of the bill, suggested this bill aligned with the governor's public call to license PBMs.

The Board took a break from 11:58 a.m. to 12:05 p.m.

Roll call was taken. The following Board members were physically present in Sacramento: Trevor Chandler, Public Member; Renee Barker, PharmD, Licensee Member; Jeff Hughes, Public Member; Claudia Mercado, Public Member; Jay Newell, MSW, Public Member; Ricardo Sanchez, Public Member; Satinder Sandhu, PharmD, Licensee Member; Maria Serpa, PharmD, Licensee Member, and Seung Oh, PharmD, Licensee Member. KK Jha, RPh, Licensee Member and Nicole Thibeau, PharmD, Licensee Member participated via Webex. A quorum was established.

12. Senate Bill 306 (Becker, 2025) Health Care Coverage: Prior Authorizations

Dr. Thibeau advised SB 306 requires a covered health care service that has been approved 90% or more of the time in the prior calendar year to be exempt from health plan or health insurer-imposed prior authorization for one year for in-network contracted providers. The measure was referred to the Assembly Health Committee. Dr. Thibeau noted this was the first time the Committee considered this measure. The Committee was recommending that the Board establish a support position on the measure. The Committee received no public comment on the measure at its June 11, 2025 meeting.

Committee Recommendation: Establish a support position

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 11 Oppose: 0 Abstain: 0 Not Present: 1

Board Member	Vote
Barker	Support
Chandler	Support
Crowley	Not Present
Hughes	Support
Jha	Support
Mercado	Support
Newell	Support
Oh	Support
Sanchez	Support
Sandhu	Support
Serpa	Support
Thibeau	Support

13. Senate Bill 470 (Laird, 2025) Bagley-Keene Open Meeting Act:
Teleconferencing

Dr. Thibeau advised SB 470 was amended and will extend the current flexibilities provided in the Bagley-Keene Open Meetings Act to January 1, 2030. The previous version of this measure would have made the current flexibilities permanent. Dr. Thibeau advised the Board relied upon the current flexibilities under the temporary provisions. The measure has been referred to the Committee on Governmental Organization.

The Board established a support position on this measure. The Committee believes the Board's current position remained appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

14. Senate Bill 497 (Wiener, 2025) Legally Protected Health Care Activity

Dr. Thibeau advised SB 497 would prohibit release of medical information related to a person seeking or obtaining gender-affirming health care or gender-affirming mental health care under specified conditions. This measure was double referred to the Judiciary and the Public Safety Committees. The Judiciary Committee considered the measure on June 17, 2025.

The Board established a support position on this measure. The Committee believed the Board's current Support position remains appropriate.

Members were provided the opportunity to comment. A member discussed the importance of the measure given recent Supreme Court decisions. California should lead the nation in advancing and protecting care. A member stated that providing estrogen to premenopausal women or testosterone to a man was also considered gender affirming care.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

15. Senate Bill 641 (Ashby, 2025) Department of Consumer Affairs and Department of Real Estate: States of Emergency: Waivers and Exemptions

Dr. Thibeau advised SB 641 would authorize boards within DCA to waive the application of certain provisions of board licensure requirements for licensees and applicants impacted by a declared federal, state, or local emergency or whose home or business is located in a declared disaster area, including certain examination, fee, and continuing education requirements. Additionally, it would require all applicants and licensees of the Board to provide the Board with an email address.

Dr. Thibeau noted should this measure be enacted, the Board will be required to pursue a regulation change related to maintaining an email address with the Board and noted that the Board would anticipate a decline in revenue. As the measure was not included on the agenda for the June 11, 2025 Committee meeting, it was not reviewed by the Committee at that meeting. The Assembly Business and Professions Committee was scheduled to consider this measure on July 8, 2025.

The Board established a support position on this measure. Vice Chairperson Thibeau noted that she believed the Board's current position remained appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

b. Discussion and Consideration of Board Regulations

Dr. Thibeau advised the Board had several regulations in various stages of promulgation. The Board had one regulation that was approved by the Office of Administrative Law, one regulation was undergoing final review by the Department of Consumer Affairs, two regulations were undergoing pre-notice review, and staff were preparing regulation documents for the ADDS self-assessment rulemaking package and revising the rulemaking package for the Board's outsourcing facility proposal.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

XVI. Licensing Committee Report

Chair Seung Oh provided a report on the Licensing Committee's meeting held on June 12, 2025. Dr. Oh thanked fellow Committee members Trevor Chandler, Renee Barker, Jessi Crowley, Claudia Mercado, and Satinder Sandhu.

a. Discussion and Consideration of Title 16, California Code of Regulations, Section 1793.8 Related to Technicians in Hospitals with Clinical Pharmacy Programs, Including Summary of Presentations Received

Dr. Oh indicated the meeting materials detailed the relevant laws and provided some background information. During the meeting, members received four presentations from different hospitals including Stanford Health Care, Cedars-Sinai Medical Center, UC San Diego Health, and Kaiser Permanente Enterprise Pharmacy.

Dr. Oh noted the presentations effectively conveyed that pharmacy technicians play a critical role in their respective hospitals in supporting pharmacists and patient care services. The presentations discussed technology used in assisting pharmacy operations and more expansive roles pharmacy technicians are playing in several areas including medication reconciliation and prior authorizations.

The Committee agreed that it was appropriate to evaluate the current legal

requirements that authorize pharmacy technician duties in the hospital setting and evaluate for potential changes. The meeting materials provided additional information about the Committee's discussion and public comment. The Committee will continue its discussion and consideration at its October 2025 meeting.

Members were provided the opportunity to comment. Members noted the value of the presentations, the importance of pharmacy technicians, and encouraged others to listen to the recordings.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative of CPhA noted appreciation for the presentations and indicated that CPhA will be holding another seminar on the technician role as it evolves over time. Another member of the public noted that it was important to remember that regulation of pharmacy technician roles and responsibilities vary nationally.

b. Discussion and Consideration of Pharmacist to Pharmacy Technician Ratio in the Inpatient Setting

Dr. Oh noted the Committee discussed the pharmacist to pharmacy technician ratio in the inpatient setting. As noted in the meeting materials, the ratio in the outpatient setting was set by statute, whereas the inpatient ratio was determined through regulation.

Dr. Oh noted the Committee was just beginning its evaluation of the ratio in the inpatient setting. During the meeting, members noted it may be appropriate to consider the variability in the roles pharmacy technicians play in the inpatient setting and draw distinctions in ratio based on these roles. Public comment spoke in support of providing flexibility to hospitals in determining ratio requirements. The Committee would continue its discussion during its next meeting.

Members were provided the opportunity to comment. Members noted that the Committee discussion was valuable and that the role of a pharmacy technician in a hospital setting varies greatly and may involve roles that do not touch medications.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

c. Discussion and Consideration of Proposed Changes to Application Questions for Individual Licenses

Dr. Oh noted the Committee would consider this item at its next meeting.

- d. Summary of Presentation, Discussion, and Consideration of Results of Pharmacist and Pharmacy Technician Workforce Surveys

Dr. Oh noted the Committee would consider this item at its next meeting.

- e. Discussion and Consideration of Licensing Statistics

Dr. Oh noted licensing statistics were included in the meeting materials.

XVII. Organizational Development Committee Report

President Oh advised that the meeting materials included updated information on the Board's budget for fiscal year 2024/25 which began July 1, 2024. The Board's authorized expenditures were anticipated to be about 35.2 million dollars this year. The Board's fund condition was expected to increase slightly at the end of the current fiscal year. According to the report provided by the DCA, the Board's fund currently has 6.5 months in reserve. Under the provisions of BPC section 4400(p), the Board shall seek to maintain a reserve equal to approximately one year's operating expenditures. As the Board's new fee structure became effective in January 2025, the Board will continue to monitor the fund and adjust in future years if needed. Dr. Oh advised Board member attendance and mail vote information was also included in the meeting materials. Dr. Oh reported the Board currently had 7 vacant staff positions and recruitments were ongoing. Dr. Oh added upcoming meeting dates and preliminary meeting dates for 2026 were included in the meeting materials. He added the July 7, 2025 Board meeting was cancelled, and the November 2025 Board meeting was meeting anticipated to take place in Southern California.

Members were provided the opportunity to comment. Members discussed how recruitments for staff positions are advertised.

Members of the public participating in Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

XVIII. Executive Officer Report

Ms. Sodergren reported on efforts made by the Department of Justice to facilitate interstate data sharing with prescription drug monitoring programs. California was currently sharing data with Oregon. Additionally, the Department of Justice reached an agreement with the Veterans Affairs (VA) which allows for one-way search capabilities by the VA.

Ms. Sodergren advised the Board's updated pharmacy law webinar was available on its learning management system. The updated version includes law changes that became effective earlier this year.

Ms. Sodergren provided an update on the actions the Board has taken in response to closures of Rite Aid pharmacies in California, including the release of a subscriber alert regarding the bankruptcy which encouraged pharmacies to begin taking steps to assist patients. The alert reminded licensees about the emergency refill provisions in BPC section 4064. In response to public comment, the Board will release this alert again. As indicated in the meeting materials, together with the Medical Board of California, Osteopathic Medical Board of California, and Department of Consumer Affairs, the Board released a joint statement regarding the closures. As noted in the joint statement, removal of the overly prescriptive requirements in Pharmacy Law as proposed in the Board's sunset measure, Assembly Bill 1503 (Berman, 2025), will mitigate impacts to patients, prescribers, and pharmacy personnel moving forward.

Ms. Sodergren advised the meeting materials also included an update on the implementation activities for the California Medication Error Reporting (CAMER) program. Additional information would be released regarding orientation dates for meetings hosted by the Institute for Safe Medication Practices. Once available, the information will be included on the Board's webpage.

Ms. Sodergren reported information was also provided in the meeting materials regarding the annual meeting of the National Association of Boards of Pharmacy.

Ms. Sodergren advised that the California State Board of Pharmacy, along with the Medical Board of California, Osteopathic Medical Board, Board of Registered Nursing, and others were hosting a joint forum to help facilitate better collaboration and understanding specifically related to access to controlled substances. The forum was tentatively scheduled for December 17, 2025, and would be convened both in person and via Webex.

Members were provided the opportunity to comment. Members discussed how VA prescriptions were not reported to CURES and the possibility of adding this as a future agenda item.

Members of the public participating in Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. Members of the public expressed concern regarding the Rite Aid closures and VA prescriptions not being included in CURES, and conveyed appreciation for the upcoming joint forum on access to controlled substances.

Ms. Sodergren indicated there was banner on the top of the Board's webpage linking to the Board's "Online Pharmacy Locator" that reminds individuals to contact their health plan to ensure the pharmacy chosen is in-network with their health plan. This was also listed in the fact sheet about pharmacy closures.

XIX. Closed Session Matters

The Board did not meet in closed session.

The meeting adjourned at 12:55 pm.